Screener
Haemonetics HAE Debt Repayments
Debt Repayments at other companies
Other financials
Where this comes from
Reported directly by Haemonetics in its filing.
Tagged under the XBRL concept us-gaap:RepaymentsOfLongTermDebt.
The source filing: Haemonetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 6:09 AM EDT
- Fiscal quarter
- Q1 FY2027
- Calendar quarter
- Q2 2026
- Accession
- 0000313143-26-000120
| Line item | Three Months Ended / June 27, 2026 | Three Months Ended / June 28, 2025 |
|---|---|---|
| Net cash used in investing activities | (22,234) | (33,000) |
| Cash Flows from Financing Activities: | ||
| Payments on revolving credit facility | (50,000) | — |
| Repayment of term loan borrowings | (1,563) | (1,563) |
| Proceeds from employee stock purchase plan | 3,123 | 3,476 |
| Proceeds from exercise of stock options | 426 | 462 |
| Cash used to net share settle employee equity awards | (3,500) | (4,781) |
| Other financing activities | (14) | (36) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Haemonetics's debt repayments?
- Haemonetics (HAE) reported debt repayments of $1.56M in Q2 2026.
- How has Haemonetics's debt repayments changed year-over-year?
- Haemonetics's debt repayments decreased by 0.0% year-over-year, from $1.56M to $1.56M.
- What is the long-term trend for Haemonetics's debt repayments?
- Over 4 years (2022 to 2026), Haemonetics's debt repayments has grown at a -100.0% compound annual growth rate (CAGR), from $17.5M to $0.
- What does debt repayments mean?
- Cash used to repay or retire outstanding debt obligations, including scheduled maturities and early redemptions.
Ask your AI about Haemonetics's debt repayments.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude